Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capivasertib + docetaxel versus placebo + docetaxel in metastatic castration-resistant prostate cancer
2021-005201-27Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Mar 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) and prostate cancer (PCa) comparing Capivasertib + docetaxel with Placebo + docetaxel (2 arms). Primary endpoint: Overall survival. Started Mar 2022; status: active.
02
Drugs
capivasertibdocetaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)prostate cancer (PCa)
Beyond the preview
Go deeper on 2021-005201-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005201-27.